Michael Jager
Overview
Explore the profile of Michael Jager including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
794
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kleine A, Mankel C, Hainthaler A, Wachtler M, Dietzek-Ivansic B, Schubert U, et al.
Inorg Chem
. 2024 Nov;
63(49):23233-23247.
PMID: 39582166
In this contribution, the divergent modular synthesis of photoredox-active dyads, triads and a tetrad descending from one ligand precursor is presented by combining "chemistry-on-the-ligand", stepwise complexation and "chemistry-on-the-complex" with minimal...
2.
Kleine A, Schubert U, Jager M
Inorg Chem
. 2024 Feb;
63(9):4053-4062.
PMID: 38373324
In this work, we present a concise modular assembly strategy using one universal heteroleptic 2,6-di(quinolin-8-yl)pyridine-based ruthenium(II) complex as a starting building block. Extending the concept from established ligand modifications and...
3.
Knell A, Bohm A, Jager M, Kerschbaum J, Engl S, Rudnicki M, et al.
Microorganisms
. 2023 Jul;
11(7).
PMID: 37512928
Patients with chronic kidney disease (CKD) or immunosuppression are at increased risk of severe SARS-CoV-2 infection. The vaccination of CKD patients has resulted in lower antibody concentrations and possibly reduced...
4.
Diem G, Jager M, Dichtl S, Bauer A, Lass-Florl C, Reindl M, et al.
Microbiol Spectr
. 2023 Apr;
11(3):e0516322.
PMID: 37098903
Rising breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4/5 led to the performance of various studies investigating systemic immunity and neutralizing antibodies in sera, but mucosal...
5.
Dichtl S, Diem G, Jager M, Zaderer V, Lupoli G, Dachert C, et al.
Antiviral Res
. 2023 Mar;
213:105581.
PMID: 36965526
The identification of the SARS-CoV-2 Omicron variants BA.4/BA.5, BF.7 and BQ.1.1 immediately raised concerns regarding the efficacy of currently used monoclonal antibody therapies. Here we examined the activity of monoclonal...
6.
Jager M, Diem G, Sahanic S, Fux V, Griesmacher A, Lass-Florl C, et al.
J Infect Dis
. 2023 Mar;
228(2):160-168.
PMID: 36869832
Background: The emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants BA.1, BA.2, and BA.4/5 demonstrate higher transmission and infection rates than previous variants of concern. To evaluate effectiveness...
7.
Jager M, Dichtl S, Bellmann-Weiler R, Reindl M, Lass-Florl C, Wilflingseder D, et al.
J Infect Dis
. 2022 Oct;
227(4):528-532.
PMID: 36315869
Omicron variants are still the dominant SARS-CoV-2 viruses worldwide, therefore determination of the level of protection from infection and severe disease is essential. Here, we investigated humoral and cellular immunity...
8.
Moradi M, Staude I, Pertsch T, Jager M, Schubert U
Nanoscale
. 2022 Aug;
14(34):12395-12402.
PMID: 35971983
The control of plasmon-nanoemitter interactions at the nanoscale enables the tailored modulation of optical properties, namely, the photoluminescence (PL) intensity of the nanoemitters. In this contribution, using a nanometer-thick poly[(2-diethylamino)...
9.
Jager M, Sonnleitner S, Dichtl S, Lafon E, Diem G, Walder G, et al.
Front Immunol
. 2022 Jul;
13:868361.
PMID: 35833113
Background: Residents of nursing homes are one of the most vulnerable groups during the severe acute syndrome coronavirus 2 (SARS-CoV-2) pandemic. The aim of this study was to characterize cellular...
10.
Lafon E, Jager M, Bauer A, Reindl M, Bellmann-Weiler R, Wilflingseder D, et al.
J Allergy Clin Immunol
. 2022 Jan;
149(4):1242-1252.e12.
PMID: 35093484
Background: Few studies have directly compared virus-specific antibodies and their neutralizing capacity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild type (WT) and circulating variants of concern despite the...